Where does Biogen MA Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Biogen MA Inc. ranks #1,662 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Biogen MA Inc. hold?

Biogen MA Inc. holds 247 US utility patents granted between 2015 and 2025, spanning 39 technology areas.

What is Biogen MA Inc.'s Innovation Score?

Biogen MA Inc. has an Innovation Score of 57.0 out of 100 (top 6% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Biogen MA Inc.'s patent grant rate increasing or decreasing?

Biogen MA Inc.'s recent grant velocity is -15% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Biogen MA Inc.'s patents?

Biogen MA Inc.'s patents average 19.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Biogen MA Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Biogen MA Inc.

Q: What technology areas does Biogen MA Inc. focus on?

Biogen MA Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 152 patents. Grants appear in 39 CPC subclasses total.

USPTO PatentsView assignee record - 247 granted patents across 39 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Biogen ranks #1,662 of 49,997 tracked US assignees by granted-patent volume, with 247 patents across 39 technology areas.

#1,662
of 49,997 US assignees by volume: Top 6%
by Innovation Score (57.0/100): 19.6
avg claims per patent: -15%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1662 · US Corporation #1,662 · 247 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 247 grants
TOP-DECILE #1,662/49,997
PHOTO-FINISH Cambridge Enterprise
CPC-FOCUS A61P · 39 areas
INNOV-PAR 57.0/100
CLAIMS-RICH 19.6 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -15% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cambridge Enterprise Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Biogen MA · this assignee

57
Exact Sciences · near

57
Mitsuboshi Belting · near

57
Politecnico DI Torino · near

57
Postech Academy-indu… · near

57
3D Lighting… · lowest

7

What this shows Biogen's Innovation Score is 57.0/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Biogen's grants concentrate

Biogen MA Inc. is a focused PatentsView assignee: 39 CPC subclasses with 61.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (38 grants) versus a trough of 12 in 2015. By volume, Biogen sits between Oregon Health & Science University and J. Choo Limited.

Biogen's three-year grant acceleration

From 2019–2021 to 2022–2024, Biogen MA Inc. moved from 85 to 53 grants (0.62x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,380. See the growth leaderboard.

Oregon Health & S…

248
Richemont Interna…

248
Teradata US

248
Water Pik

248
Cambridge Enterpr…

247
H LEE Moffitt Can…

247
Honeywell Federal…

247
J Choo

247
Biogen MA ◀

247

What this shows Biogen holds 247 patents at rank #1,662, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Biogen

By rank, the assignees closest to #1,662 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Biogen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Biogen, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (57 here).

Postech Academy-industry Foundation 57 Mitsuboshi Belting Ltd. 57 Exact Sciences Corporation 57 Politecnico DI Torino 57

Similar claim depth

Nearest assignees by average claims per patent (19.6 here).

Carnegie Mellon University 19.6 avg Amazon Technologies, Inc. 19.6 avg Aviat U.S., Inc. 19.6 avg Entropic Communications, LLC 19.6 avg

Biogen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

57 Top 6% higher than 94% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Biogen MA Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	12	4.9%
2016	24	9.7%
2017	38	15.4%
2018	21	8.5%
2019	31	12.6%
2020	20	8.1%
2021	34	13.8%
2022	21	8.5%
2023	18	7.3%
2024	14	5.7%
2025partial year	14	5.7%

Which technologies does Biogen MA Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 152

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 127

C07K - Peptides 95

C07D - Heterocyclic Compounds 71

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 57

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 42

Y02A - Technologies FOR Adaptation TO Climate Change 33

C07C - Acyclic OR Carbocyclic Compounds 19

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 18

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 15

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 10

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 10

A61B - DIAGNOSIS; SURGERY; Identification 10

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 10

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 7

Top 15 of 39 technology areas

Where it ranks

Overall rank by patents

#1,662

of 49,997 tracked assignees

Innovation Score

57.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Biogen MA Inc.'s patent record in context - here's where to go next.

Biogen MA Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 61.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,662 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Biogen MA Inc. against Oregon Health & Science University, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 57.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.